Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49
patients with low-grade NMIBC with the aim to determine the overall response to
administration of oral metformin for 3 months in a marker tumour deliberately left following
transurethral resection of multiple, papillary NMIBC tumours.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators:
Jeroen Bosch Ziekenhuis Radboud University Sint Franciscus Gasthuis